North America & Europe Region to Remain One of the Leading Markets for Psoriatic Arthritis (PsA) Treatment Through 2028
Nearly 70% of the psoriasis patient population is prone to psoriatic arthritis, and up to 20% of arthritis patients are susceptible to acquire psoriasis, according to the recent findings of the Arthritis Foundation. The rate of increasing burden of psoriasis and psoriatic arthritis on healthcare industry has been boosting clinical research in the field of psoriatic arthritis, in recent years. Sustained adoption of conventional disease modifying anti-rheumatic drugs (DMARDs), especially in cost sensitive regions, is projected to push the demand...
View full press release